Sonoma Pharmaceuticals
Filed with the SEC on · accession 0001683168-26-008495
SNOA filed a 10-Q (quarterly report) with the SEC on Nov 10, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +0.9% by the first close after the filing.
Sonoma Pharmaceuticals filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing routine financial results and capital structure details including an at-the-market offering and an underwriting agreement.
Close before
$1.13
Nov 9, 2026
First close after
+0.88%
$1.14
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for SNOA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SNOA?
Click hereSNOA filed a 10-Q (SEC filing). Sonoma Pharmaceuticals filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing routine financial results and capital structure details including an at-the-market offering and an underwriting agreement.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
SNOA closed at $1.13 before the filing and $1.14 on Nov 10, 2026 (+0.88%).
Get alerts when SNOA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days